Unlock instant, AI-driven research and patent intelligence for your innovation.
Medicinal composition and application thereof
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A kind of composition and medicine technology, applied in the pharmaceutical composition and its application field, can solve the problems such as the treatment effect is not ideal enough
Active Publication Date: 2013-01-30
JIANGSU KANION PHARMA CO LTD +1
View PDF5 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
Prostatic hyperplasia is a group of diseases with multiple etiologies and requires long-term medication. If synthetic drugs such as α1-receptor blockers and 5α-reductase inhibitors that only target a specific target point have certain side effects during long-term use, such as Hypotension, impotence, sexual dysfunction, headache, etc., and the treatment effect is not satisfactory, thus limiting the application of these drugs in the treatment of benign prostatic hyperplasia
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1～31
[0113] Linolenic acid, palmitic acid, N-(2-hydroxyethyl), 9,12,15-octadecatrienamide, glyceryl linolenate, 15 , 16-dihydroxylinoleic acid, ethyl linolenate, glyceryl palmitate, 24-methylenecholesteryl palmitate, 1,3-dipalmitic acid-2-linolenic acid triglyceride, 1,3- Dilinolenic acid-2-palmitic acid triglyceride, 24-methylene cholesteryl linolenate, cycloalkenyl eucalyptol linolenate, pollen alkanol sterol linoleate, 1,3-dipalmitic acid diglyceride, 1-palmitic acid-2-heptadecanoic acid diglyceride, kaempferol, quercetin, isorhamnetin, gossin, kaempferol 7-O-(6'-rhamnosyl) glucoside, N 1 , N 5 , N 10 -Three-(E)-coumaroylpermidine, N 1 , N 5 , N 10-Tris-(Z)-coumaroylperamidine, 1-O-(β-D-glucose)-(2S,3S,4R)-2N-[(2′R)-2′-Hydroxytetradecanoyl Acenoic acid]-octadecene-3,4-diol, putrescine and indole-3-acetic acid are mixed according to the components and contents described in Table 1 to obtain the pharmaceutical composition of the present invention.
[0114] Wherein, the pre...
Embodiment 29
[0194] Test product: Example 29: by mass percentage, the plant extract of fatty acid compounds is 45%, the proportioning of plant extract of flavonoid compounds is 35% and the plant extract of alkaloid compounds is 20%, and fatty acids, flavonoids are combined These three types of compounds of flavonoids and alkaloids obtain the anti-prostatic hyperplasia pharmaceutical composition of the present invention (wherein the active ingredients are about mass percent: 40% of fatty acid compounds, 30% of flavonoids and 10% of alkaloids) .
[0195] Positive control substance:
[0196] For Qianliekang (Pulean Tablets), the maximum clinical dosage for a 60 kg adult is 12 tablets / d.
[0197] Rat dose determination: According to the conversion relationship between human and animal effective doses, the rat dose is calculated as 6 times the clinical dose of a 60 kg adult, that is, 1.2 tablets / kg. Preparation method: Take 36 Qianliekang tablets, use distilled water as solvent, add Tween-80 ...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention discloses a medicinal composition, which comprises two or three of a, b and c, wherein a is long-chain fatty acid compounds of a formula I or plant extract containing the same; b is flavonoid compounds of a formula II or plant extract containing the same; and c is the following alkaloid compounds or plant extract containing the same: N1,N5,N10-tri-(E / Z)-coumaroyl spermidine, 1-O-(beta-D-glucose)-(2S, 3S, 4R)-2N-[(2'R)-2'-hydroxytetracosenoicacid]-octadecylene-3,4-diol, putrescine and indol-3-acetic acid. The medicinal composition of the invention can be used for preparing aromatizing enzyme inhibitor, 5alpha reductase inhibitor, alpha1-adrenergic receptor antagonist, cyclooxygenase-2 inhibitor, prostate-specific antigen (PSA) secretion inhibitor, anti-inflammation medicamentor medicament for resisting prostatic hyperplasia, prostatitis or prostatic cancer.
Description
technical field [0001] The invention belongs to the field of pharmaceutical compositions, in particular to a pharmaceutical composition and its application. Background technique [0002] Benign prostatic hyperplasia (BPH) is a common physiological lesion in elderly men. When the lesion causes a series of symptoms such as urinary obstruction, it is called benign prostatic hyperplasia. Autopsy reports of 1075 cases abroad showed that: at the age of 25 to 30, 10% of men could see early benign prostatic hyperplasia lesions under the microscope; as the age increases, the incidence of benign prostatic hyperplasia diagnosed by histology also increases accordingly; By the age of 51 to 60, the incidence rate increases to 75%; by the age of 85, about 90% of men have histological BPH. It can be seen from the above that with the acceleration of population aging in my country, the incidence of benign prostatic hyperplasia caused by old age continues to rise, and benign prostatic hyperpl...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More 
